Skip to main content

Table 1 Primary AML samples used for in-vitro investigations

From: The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us